Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third quarter, officially becoming the world’s best-selling drug. Lilly is working to shore ...

Olympic champion Lilly King tied the knot with James Wells this weekend. The ceremony took place in Maine with several teammates and figures in the swimming world in attendance. Lilly King and Wells ...

Lilly King, an Indiana University alum and one of American swimming's greats, married James Wells over the weekend. King, a 28-year-old Evansville native and three-time Olympic gold medalist, retired ...

Lilly Aspell is Scottish-born actress famous for portraying Young Diana (Gal Gadot) in Wonder Woman and Wonder Woman 1984 . Born in Kilmarnock, Ayrshire, Lilly is a keen equestrian and combines both ...

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

Eli Lilly & Co. halted a study of an experimental drug designed to prevent obesity patients from losing too much muscle, citing strategic business reasons it didn’t disclose. Lilly closed the trial on ...

A computer-generated image of a large manufacturing facility. A computer-generated image of Eli Lilly and Company’s planned drug chemical plant in Houston Credit: Eli Lilly and Company Eli Lilly and ...

Shooting 96 episodes in 90 days was never a recipe for success, the YouTube star said on 'The Julia Cunningham Show.' By Etan Vlessing Canada Bureau Chief “I don’t want to say you were set up to fail.

US appeals court in Chicago upholds jury verdict, damages Jury found Lilly didn't rebate Medicaid for higher prices Lilly disagrees with decision, plans appeal Sept 11 (Reuters) - A federal appeals ...

As the oral GLP-1 race intensifies, Eli Lilly has slimmed back the number of phase 2 trials it is conducting for one of its contenders. The Big Pharma had been running three midstage studies of the ...